MR- PET Guided Biologically Optimised Interstitial Brachytherapy

Cervical Cancer Clinical Trial

— MR-PET Brachy  

Official title:

MR-PET Guided Biologically Optimised Interstitial Brachytherapy for Postoperative Recurrent Cervical Cancers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01391065
• Other study ID #: TMH-IRB 843
• Status: Completed
• Phase: N/A
• Start date: February 23, 2011
• Est. completion date: October 4, 2019

Study information

• Verified date: April 2020
• Source: Tata Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed two stage study will evaluate patterns of local recurrence after EBRT and brachytherapy in spatial reference to baseline functional MRI and FLT/F-Miso PET scan in patients undergoing chemoradiotherapy for postoperative recurrences of cervical cancer. The first stage of the study will focus on developing MR guided interstitial brachytherapy and validating the concept of high risk gross tumor volume (on the basis of functional imaging features).

The second stage thereafter will focus on developing biologically modulated interstitial brachytherapy.

In the proposed two staged study the investigators intend to prospectively evaluate and validate concept of HRGTV and develop technique of biologically dose modulated brachytherapy. The demonstration of technical feasibility and clinical safety of biologically modulated image guided radiotherapy in this pilot study for may pave the way for improving local control in patients with postoperative recurrences.

Description:

Aims

Stage I

Aim 1: To spatially characterize biologically heterogenous subvolumes within the gross tumor through multimodality (18 F-Miso/FLT/Functional MR) image fusion.

Aim 2: To evaluate post external beam radiotherapy (EBRT) response in spatial reference to biological heterogeneous sub-volumes on imaging.

Stage II:

Aim 3: To evaluate technical feasibility of delivering dose modulated biologically optimized interstitial brachytherapy.

Aim 4: To evaluate acute and late toxicity and quality of life associated with biologically optimized brachytherapy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 4, 2019
• Est. primary completion date: February 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age > 18 years.

• ECOG 0 or 1.

• Residual/ Recurrent tumor after hysterectomy of cervical cancer.

• No visceral metastasis.

• No known contraindication to contrast enhanced MRI/PET scan.

• Fit for radical treatment (radiotherapy+/-chemotherapy).

Exclusion Criteria:

• Expected survival less than 3 years due to coexisting morbid medical conditions precluding radical chemoradiotherapy.

• Inguinal or extra-pelvic nodal metastasis (Patients with common iliac nodal enlargement in the absence of paraaortic nodal metastasis on PET-CT may be included in the study).

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Radiation:
• MR PET Guided Brachytherapy

Locations

Country	Name	City	State
India	Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre	Navi Mumbai	Maharashtra

Sponsors (1)

Lead Sponsor	Collaborator
Tata Memorial Hospital

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Local Response in spatial reference to High Risk GTV (as identified by functional imaging)		3 months after treatment completion
Secondary	Incidence of Grade III rectal and bladder toxicity with biologically dose modulated brachytherapy	Stage II involves dose modulated brachytherapy wherein higher dose will be delivered to biologically high risk target volume. Saftey will be assessed initially by an interim analysis undertaken at 50 % accrual(median follow up 1 yr). If incidence of grade III-IV rectal and bladder toxicity >15% than the trial will be stopped else continued till target accrual. The technique will be considered to be safe if Grade III bladder and bowel toxicity remain to be under 15%.	2 years after treatment conclusion